About InorbitTX

Inorbit Therapeutics AB

Inorbit Therapeutics AB (InorbitTX) was founded in 2015.  It is a privately owned virtual Drug Discovery and Development company based in the BioVentureHub in Mölndal, near Gothenburg, Sweden.  We focus our small molecule drug discovery and development expertise on areas with a high unmet medical need and an excellent market perspective with a special interest for Non Alcoholic Steato Hepatitis (NASH). InorbitTX applies a unique groundbreaking chemotype to generate its potential new drugs. This chemotype is specifically designed to mitigate the risk for Drug Induced Liver Injury (DILI), a major cause for drug failure in late stages of development and even after approval and marketing.  Its current lead compound, the Farnesoid X Receptor (FXR) agonist IOT022, aimed for the treatment of NASH, shows excellent efficacy in a sub-chronic in vivo model with an excellent safety margin.

Our leaders have long and successful track records in drug discovery and Development.


Our CEO, Dr. Bert Benthem, born 1962

  • has held senior positions in the Drug Discovery and Development area with Piramal Healthcare, AstraZeneca, 7TM Pharma and NovoNordisk,
  • has brought several discovery programs to the clinic,
  • has a pertinent academic background holding an MSc in Biology and a PhD in Medicine, with specialty in Medical Physiology, both from the University of Groningen, The Netherlands,
  • has focused his research on metabolic diseases, including NAFLD / NASH, and
  • has published about 40 scientific papers in peer reviewed journals.

Our CSO, Dr. Robert Judkins, born 1972

  • has been team leader in the Medicinal Chemistry department with AstraZeneca,
  • has 20 years of experience in small molecule drug discovery with AZ, Millennium Pharmaceutical, Cambridge Discovery Chemistry and Roche, and
  • has a proven track record of medicinal chemistry in drug discovery and patent strategy.

Leadership is supported by the Board of Directors:

Bert Benthem, PhD, (chair, see above)

Wim Mol, Phd, CEO at Immunovo BV, a privately held company based in Den Bosch, The Netherlands. Wim carries over 20 years of international experience in general management, commercial and R&D positions in the pharmaceutical industry.

Louise Warme, MD, investment manager at ALMI Invest, Sweden’s most active venture capitalist investing in start-ups.  Louise brings a broad experience from (pre-)clinical research, med-tech, and the investment milieu.

Johannes Bruski, PhD, partner in Astadis Capital, a private trading and investment group.  Before establishing Astadis, Johannes was a partner in Allen & Overy LLP.  After practicing in Frankfurt, Germany, he was seconded to their associated firm Khoshaim & Associates in Riyadh and resided there for the last ten years. He continues to support Khoshaim & Associates as a senior consultant, and he currently also serves as a special advisor to the Saudi Ministry of Commerce and Investment. He has worked on many private and public mergers, acquisitions and joint ventures, both for strategic and for venture capital/private equity investors, and on other corporate and structured finance transactions.